Adaptimmune Therapeutics Plc ADR (ADAP)’s Day in Review: Closing at 1.02, Down by -0.97

Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

After finishing at $1.03 in the prior trading day, Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed at $1.02, down -0.97%. In other words, the price has decreased by -$0.97 from its previous closing price. On the day, 1.07 million shares were traded. ADAP stock price reached its highest trading level at $1.06 during the session, while it also had its lowest trading level at $1.01.


Our goal is to gain a better understanding of ADAP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.81 and its Current Ratio is at 2.81. In the meantime, Its Debt-to-Equity ratio is 0.97 whereas as Long-Term Debt/Eq ratio is at 0.76.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on May 30, 2024, initiated with a Sector Outperform rating and assigned the stock a target price of $3.15.

On March 24, 2023, Bryan Garnier started tracking the stock assigning a Buy rating and target price of $3.60.

Guggenheim Upgraded its Neutral to Buy on January 03, 2023, while the target price for the stock was maintained at $5.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 17 ’24 when Rawcliffe Adrian sold 30,080 shares for $0.67 per share. The transaction valued at 20,244 led to the insider holds 44,848 shares of the business.

Bertrand William C JR sold 18,908 shares of ADAP for $12,725 on Jan 17 ’24. The Chief Operating Officer now owns 7,785 shares after completing the transaction at $0.67 per share. On Jan 17 ’24, another insider, Norry Elliot, who serves as the Chief Medical Officer of the company, sold 18,276 shares for $0.67 each. As a result, the insider received 12,300 and left with 7,785 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 260673232 and an Enterprise Value of 1444079360. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.22 while its Price-to-Book (P/B) ratio in mrq is 10.69. Its current Enterprise Value per Revenue stands at 78.662 whereas that against EBITDA is -7.852.

Stock Price History:

Over the past 52 weeks, ADAP has reached a high of $2.05, while it has fallen to a 52-week low of $0.42. The 50-Day Moving Average of the stock is -12.05%, while the 200-Day Moving Average is calculated to be 9.79%.

Shares Statistics:

The stock has traded on average 1.70M shares per day over the past 3-months and 3232390 shares per day over the last 10 days, according to various share statistics. A total of 227.17M shares are outstanding, with a floating share count of 226.14M. Insiders hold about 11.49% of the company’s shares, while institutions hold 52.00% stake in the company. Shares short for ADAP as of 1715731200 were 3441159 with a Short Ratio of 2.02, compared to 1713139200 on 3407756. Therefore, it implies a Short% of Shares Outstanding of 3441159 and a Short% of Float of 2.02.

Most Popular